293 related articles for article (PubMed ID: 31959227)
1. Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype.
Chen XQ; Zhang F; Su QC; Zeng C; Xiao FH; Peng Y
Clin Epigenetics; 2020 Jan; 12(1):16. PubMed ID: 31959227
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer.
Chen XQ; Zhang F; Xiao FH; Peng Y
Breast Cancer; 2021 Nov; 28(6):1252-1260. PubMed ID: 33966175
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
Fackler MJ; Umbricht CB; Williams D; Argani P; Cruz LA; Merino VF; Teo WW; Zhang Z; Huang P; Visvananthan K; Marks J; Ethier S; Gray JW; Wolff AC; Cope LM; Sukumar S
Cancer Res; 2011 Oct; 71(19):6195-207. PubMed ID: 21825015
[TBL] [Abstract][Full Text] [Related]
4. Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesis.
Romagnolo DF; Papoutsis AJ; Laukaitis C; Selmin OI
BMC Cancer; 2015 Dec; 15():1026. PubMed ID: 26715507
[TBL] [Abstract][Full Text] [Related]
5. Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma.
Galamb O; Kalmár A; Barták BK; Patai ÁV; Leiszter K; Péterfia B; Wichmann B; Valcz G; Veres G; Tulassay Z; Molnár B
World J Gastroenterol; 2016 Dec; 22(47):10325-10340. PubMed ID: 28058013
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation and hormone receptor status in breast cancer.
Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
[TBL] [Abstract][Full Text] [Related]
7. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
[TBL] [Abstract][Full Text] [Related]
8. DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer.
Awada Z; Nasr R; Akika R; Cahais V; Cuenin C; Zhivagui M; Herceg Z; Ghantous A; Zgheib NK
Clin Epigenetics; 2019 Oct; 11(1):138. PubMed ID: 31601247
[TBL] [Abstract][Full Text] [Related]
9. Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer.
Di Cello F; Cope L; Li H; Jeschke J; Wang W; Baylin SB; Zahnow CA
PLoS One; 2013; 8(7):e68630. PubMed ID: 23844228
[TBL] [Abstract][Full Text] [Related]
10. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
11. Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.
Fernandez-Jimenez N; Sklias A; Ecsedi S; Cahais V; Degli-Esposti D; Jay A; Ancey PB; Woo HD; Hernandez-Vargas H; Herceg Z
Epigenetics; 2017; 12(11):964-972. PubMed ID: 29099283
[TBL] [Abstract][Full Text] [Related]
12. Alternative methylation of intron motifs is associated with cancer-related gene expression in both canine mammary tumor and human breast cancer.
Nam AR; Lee KH; Hwang HJ; Schabort JJ; An JH; Won SH; Cho JY
Clin Epigenetics; 2020 Jul; 12(1):110. PubMed ID: 32693820
[TBL] [Abstract][Full Text] [Related]
13. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
de Almeida BP; Apolónio JD; Binnie A; Castelo-Branco P
BMC Cancer; 2019 Mar; 19(1):219. PubMed ID: 30866861
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing.
Sun Z; Asmann YW; Kalari KR; Bot B; Eckel-Passow JE; Baker TR; Carr JM; Khrebtukova I; Luo S; Zhang L; Schroth GP; Perez EA; Thompson EA
PLoS One; 2011 Feb; 6(2):e17490. PubMed ID: 21364760
[TBL] [Abstract][Full Text] [Related]
15. Identification of aberrantly methylated differentially expressed genes in breast cancer by integrated bioinformatics analysis.
Yi L; Luo P; Zhang J
J Cell Biochem; 2019 Sep; 120(9):16229-16243. PubMed ID: 31081184
[TBL] [Abstract][Full Text] [Related]
16. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.
Mao Y; Fu A; Hoffman AE; Jacobs DI; Jin M; Chen K; Zhu Y
Tumour Biol; 2015 May; 36(5):3533-9. PubMed ID: 25740058
[TBL] [Abstract][Full Text] [Related]
17. Enrichment of CpG island shore region hypermethylation in epigenetic breast field cancerization.
Muse ME; Titus AJ; Salas LA; Wilkins OM; Mullen C; Gregory KJ; Schneider SS; Crisi GM; Jawale RM; Otis CN; Christensen BC; Arcaro KF
Epigenetics; 2020 Oct; 15(10):1093-1106. PubMed ID: 32255732
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer.
Li L; Lee KM; Han W; Choi JY; Lee JY; Kang GH; Park SK; Noh DY; Yoo KY; Kang D
Hum Mol Genet; 2010 Nov; 19(21):4273-7. PubMed ID: 20724461
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.
Hill VK; Ricketts C; Bieche I; Vacher S; Gentle D; Lewis C; Maher ER; Latif F
Cancer Res; 2011 Apr; 71(8):2988-99. PubMed ID: 21363912
[TBL] [Abstract][Full Text] [Related]
20. Survival differences of CIMP subtypes integrated with CNA information in human breast cancer.
Wang H; Yan W; Zhang S; Gu Y; Wang Y; Wei Y; Liu H; Wang F; Wu Q; Zhang Y
Oncotarget; 2017 Jul; 8(30):48807-48819. PubMed ID: 28415743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
